Login to Your Account



Cabrellis' $27.5M Series A To Fund Three SCLC Trials

By Karen Pihl-Carey


Tuesday, August 8, 2006
A Conforma Therapeutics Corp. spinout, barely three months old, closed a $27.5 million Series A financing to cover Phase II trials of its only product, Calsed, to treat small-cell lung cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription